References: Oral Immunotherapy for Food Allergy

ASCIA HP References OIT Food Allergy 2022153.35 KB

Buchanan, A. D., Green, T. D., Jones, S. M., Scurlock, A. M., Christie, L., Althage, K. A., … Buks, A. W. (2007). Egg oral immunotherapy in non-anaphylactic children with egg allergy. J Allergy Clin Immunol, 19(1), 199-205. https://doi.org/10.1016/j.jaci.2006.09.016

Chinthrajah, R. S., Cao, S., Dunham, T., Sampath, V., Chandra, S., Chen, M., Sindher, S., Nadeau, K. (2020). Oral Immunotherapy for peanut allergy: The pro argument. WAO Journal, 13(8). https://doi.org/10.1016/j.waojou.2020.100455

Chu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., … Schünemann, H. J. (2019). Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. The Lancet, 393 (10187), p2222-2232. www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30420-9/fulltext

de Silva et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis. Allergy 2022 (GA²LEN publication):

https://onlinelibrary.wiley.com/doi/10.1111/all.15211

DunnGalvin, A., McMahon, S., Ponsonby, A. L., Hsia, K. C., & Tang. M. L. K. (2017). The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life. Allergy, 73(3), 560-568. https://doi.org/10.1111/all.13330

Epstein-Rigbi, N., Goldberg, M. R., Levy, M.B., Nachshon, L., & Elizur, A., (2019). Quality of Life of Food-Allergic Patients Before, During, and After Oral Immunotherapy. J Allergy Clin Immunol in Practice. 7(2), 429-436. https://doi.org/10.1016/j.jaip.2018.06.016

Fiocchi, A., Artesani, M.C., Fierro, V., Riccardi, C., Dahdah, L., Mennini, M. (2020). Oral Immunotherapy for peanut allergy: The Con argument. WAO Journal, 13(8). https://doi.org/10.1016/j.waojou.2020.100445

Grzeskowiak, L. E., Tao, B., Knight, E., Cohen-Woods, S., & Chataway, T. (2020). Adverse events associated with peanut oral immunotherapy in children – a systematic review and meta-analysis. Scientific Reports, 10, 659. https://doi.org/10.1038/s41598-019-56961-3

Jones et al. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022: https://doi.org/10.1016/S0140-6736(21)02390-4

Nurmatov, U., Dhami, S., Arasi, S., Pajno, G. B., Fernandez‐Rivas, M., Muraro, A., … Sheikh, A. (2017). Allergen immunotherapy for IgE‐mediated food allergy: a systematic review and meta‐analysis. Allergy, 72(8). https://doi.org/10.1111/all.13124

Shaker et al. (2021). The cost-effectiveness of preschool peanut oral immunotherapy in the real-world setting. J Allergy Clin Immunol Pract. https://doi.org/10.1016/j.jaip.2021.02.058

Tang, M. L. K., Ponsonby, A-L., Francesca Orsini, F., Dean Tey, D, Marnie Robinson M., Su, E. L., … Donath, S. (2015). Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol, 135(3), 737-744. https://doi.org/10.1016/j.jaci.2014.11.034

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

ASCIA resources are based on published literature and expert review, however, they are not intended to replace medical advice. The content of ASCIA resources is not influenced by any commercial organisations.

For more information go to www.allergy.org.au

To donate to immunology/allergy research go to www.allergyimmunology.org.au